Literature DB >> 15015767

Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas.

Masaki Okada1, Keisuke Miyake, Yoshihito Matsumoto, Nobuyuki Kawai, Katsuzo Kunishio, Seigo Nagao.   

Abstract

BACKGROUND: We studied whether or not the expressions of MMP-2 and MMP-9 were correlated with the proliferative potential or recurrence of intracranial meningiomas.
METHODS: The expressions of MMP-2 and MMP-9 of 56 meningioma tissues were examined and scored by immunohistochemistry (IHC). Expressions of the mRNA of each MMP were also examined by reverse transcriptase polymerase chain reaction (RT-PCR) assay in 15 cases. The relationships between IHC score and each of age, sex, tumor location, histology, MIB-1 labeling index (LI), and recurrence or regrowth rate were studied.
RESULTS: Nine of 56 cases showed recurrence or regrowth. IHC revealed that MMP-2 was highly expressed in 13 of 56 cases, whereas MMP-9 was highly expressed in 22 of 56 cases. Among the 15 cases analyzed by RT-PCR assay, MMP-2 and MMP-9 were expressed in 9 and 13 cases, respectively. Based on the Kaplan-Meier curve, the high expressions of MMPs were related to recurrence/regrowth (MMP-2: p < 0.001; MMP-9: p < 0.05). No significant relationship was observed between the expressions of MMPs and either age, sex, tumor location, or MIB-1 LI.
CONCLUSIONS: Our study indicated that MMP-2 and MMP-9 expressions are prognostic factors predicting the recurrence of meningioma, independent of proliferative potential.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15015767     DOI: 10.1023/b:neon.0000013474.01161.58

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  Secretion of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by meningiomas detected by cell immunoblot analysis.

Authors:  T Mizoue; H Kawamoto; K Arita; A Tominaga; K Kurisu
Journal:  Acta Neurochir (Wien)       Date:  1999       Impact factor: 2.216

Review 2.  Matrix metalloproteinases and their biological function in human gliomas.

Authors:  S K Chintala; J C Tonn; J S Rao
Journal:  Int J Dev Neurosci       Date:  1999 Aug-Oct       Impact factor: 2.457

3.  Histological subtypes and prognostic problems in meningiomas.

Authors:  K Jellinger; F Slowik
Journal:  J Neurol       Date:  1975       Impact factor: 4.849

4.  Expression of matrix metalloproteinases and their inhibitors in human brain tumors.

Authors:  R Béliveau; L Delbecchi; E Beaulieu; N Mousseau; Z Kachra; F Berthelet; R Moumdjian; R Del Maestro
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

5.  Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms.

Authors:  J Jäälinojä; R Herva; M Korpela; M Höyhtyä; T Turpeenniemi-Hujanen
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

6.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas.

Authors:  A Nakano; E Tani; K Miyazaki; Y Yamamoto; J Furuyama
Journal:  J Neurosurg       Date:  1995-08       Impact factor: 5.115

7.  Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors.

Authors:  J S Rao; P A Steck; S Mohanam; W G Stetler-Stevenson; L A Liotta; R Sawaya
Journal:  Cancer Res       Date:  1993-05-15       Impact factor: 12.701

8.  Cytogenetic analysis of aggressive meningiomas: possible diagnostic and prognostic implications.

Authors:  A Perry; R B Jenkins; R J Dahl; C A Moertel; B W Scheithauer
Journal:  Cancer       Date:  1996-06-15       Impact factor: 6.860

9.  Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors.

Authors:  T Nakagawa; T Kubota; M Kabuto; K Sato; H Kawano; T Hayakawa; Y Okada
Journal:  J Neurosurg       Date:  1994-07       Impact factor: 5.115

10.  Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.

Authors:  P A Forsyth; H Wong; T D Laing; N B Rewcastle; D G Morris; H Muzik; K J Leco; R N Johnston; P M Brasher; G Sutherland; D R Edwards
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

View more
  12 in total

1.  Immunohistochemical characterization of brain-invasive meningiomas.

Authors:  Thomas Backer-Grøndahl; Bjørnar H Moen; Magnus B Arnli; Kathrin Torseth; Sverre H Torp
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  MMP-9 expression in meningiomas: a prognostic marker for recurrence risk?

Authors:  V Barresi; E Vitarelli; G Tuccari; G Barresi
Journal:  J Neurooncol       Date:  2010-07-21       Impact factor: 4.130

3.  Possible role of matrix metalloproteinase in osteolytic intracranial meningiomas.

Authors:  Hyung-Sik Moon; Shin Jung; Tae-Young Jung; Van Thang Cao; Kyung-Sub Moon; In-Young Kim
Journal:  J Korean Neurosurg Soc       Date:  2010-01-31

4.  Overexpression of cyclin D1 in meningioma is associated with malignancy grade and causes abnormalities in apoptosis, invasion and cell cycle progression.

Authors:  Gang Cheng; Leiming Zhang; Wenying Lv; Chao Dong; Yaming Wang; Jianning Zhang
Journal:  Med Oncol       Date:  2014-12-13       Impact factor: 3.064

5.  Deficiency of the protein-tyrosine phosphatase DEP-1/PTPRJ promotes matrix metalloproteinase-9 expression in meningioma cells.

Authors:  Astrid Petermann; Yvonn Stampnik; Yan Cui; Helen Morrison; Doreen Pachow; Nadine Kliese; Christian Mawrin; Frank-D Böhmer
Journal:  J Neurooncol       Date:  2015-02-12       Impact factor: 4.130

6.  Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas.

Authors:  Nunung Nur Rahmah; Keiichi Sakai; Jun Nakayama; Kazuhiro Hongo
Journal:  Neurosurg Rev       Date:  2009-10-28       Impact factor: 3.042

7.  Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas.

Authors:  Alexandros Theodoros Panagopoulos; Carmen Lucia Penteado Lancellotti; José Carlos Esteves Veiga; Paulo Henrique Pires de Aguiar; Alison Colquhoun
Journal:  J Neurooncol       Date:  2008-04-17       Impact factor: 4.130

8.  Antigen expression on recurrent meningioma cells.

Authors:  Andrej Vranic
Journal:  Radiol Oncol       Date:  2010-05-24       Impact factor: 2.991

9.  Proteins involved in regulating bone invasion in skull base meningiomas.

Authors:  Fateme Salehi; Shahrzad Jalali; Ryan Alkins; Joon-Il Lee; Shelly Lwu; Kelly Burrell; Fred Gentili; Sidney Croul; Gelareh Zadeh
Journal:  Acta Neurochir (Wien)       Date:  2012-12-13       Impact factor: 2.216

10.  In vivo imaging of cell proliferation in meningioma using 3'-deoxy-3'-[18F]fluorothymidine PET/MRI.

Authors:  Asma Bashir; Tina Binderup; Mark Bitsch Vestergaard; Helle Broholm; Lisbeth Marner; Morten Ziebell; Kåre Fugleholm; Andreas Kjær; Ian Law
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-02-11       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.